Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort - Wikidata - wikimedia - TriplyDB

Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort

Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort

http://www.wikidata.org/entity/Q28478435

about

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions Innate immune responses in hepatitis C virus infection Advancement in the development of models for hepatitis C research.Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4)Liver immunology.Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-κB-mediated gene transcription Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.Detection of allele specific differences in IFNL3 (IL28B) mRNA expression Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.Prioritizing genetic variants for causality on the basis of preferential linkage disequilibrium.Pharmacogenomics of hepatitis C infections: personalizing therapy.Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients.Interferon Lambda: Modulating Immunity in Infectious Diseases.The IFN-λ Genetic Polymorphism Association With the Viral Clearance Induced by Hepatitis C Virus Treatment in Pakistani Patients.Genetics of IL28B and HCV--response to infection and treatment.The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections.Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections.Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.Epigenetic analysis of the IFNλ3 gene identifies a novel marker for response to therapy in HCV-infected subjects.A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance.Allele-specific PCR for determination of IL28B genotype Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance.Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus.Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.From genetic association studies to the biology of interleukin-28B in hepatitis C virus infection and beyond.Hepatic interferon-gamma-induced protein-10 expression is more strongly associated with liver fibrosis than interleukin-28B single nucleotide polymorphisms in hepatocellular carcinoma resected patients with chronic hepatitis C.Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection.

P2860

Q24307721-020F5B63-7F82-4E90-874C-811B13D50FBB Q27014831-47839DE2-F20E-4B18-B05B-62ECB5E64675 Q27023055-E0BDEB73-CA63-47A0-B8AA-592066D635F8 Q30418069-D2691264-217C-4FA5-B286-6EB25B4FF7E0 Q34350873-1BA3EAED-C127-4844-9C06-2E5242492A5A Q34359990-2AD3538B-911C-4501-8215-AB05664AD5F0 Q34539324-A0C13DCA-9E59-4CB6-8AD9-9A25401618E2 Q35014462-43C0CFF1-64DB-4BC4-8D69-C9D70AB001D0 Q35197060-1B948F4B-0132-4EF1-9E1A-99E3388AD1A7 Q35306683-ECCC4635-4D90-40FB-A364-800BAC41EB66 Q35995923-0ABC7E08-2068-44A3-A753-C1D7F9EEE6C3 Q36439331-1EF0BB95-9883-40B8-84A6-402127EF5363 Q36632938-9AF5BC7F-E4E6-4EAA-8AB4-60B35CF693EB Q37507757-FB5AD3C5-BD50-4FAE-ABCB-87F556BA1DAD Q37670446-D5A017A2-E742-4AA1-9D52-F7F0273F0F51 Q37699253-89CD3AC5-CC6B-43E1-B7B2-B3690FF14E2A Q38013941-8D872793-101B-48BC-AE57-8BB0DD1EF81B Q38514365-AE2474D2-F002-4EC9-A711-AF16DFE1FD8B Q38859455-07C588A8-6690-41C2-825C-CE38F0C38904 Q38926063-3EC5BFA9-85BC-4EC5-93E7-F0CEA1BC5512 Q40420673-317FFEC9-D0F3-4AB3-9E23-7836A9CB6582 Q41065262-E6FB598B-7820-43D2-AEEF-D729F479473F Q41637827-0FDE0F79-4102-403A-95B7-0402E551713F Q41715697-C968FDEC-AB22-46F2-A413-93518FB2E067 Q42232134-C62B9D6C-3934-45A3-9C15-849D61EC793F Q42236944-FA3BC3F2-2CAB-4A0E-AF72-E5E5BC2120E5 Q42982920-57ED8ACA-7375-4F4F-BE8D-3D1C9EF78912 Q42987491-C004897F-E620-40CD-8EF3-955B45EB0FC1 Q45047464-BA4AD606-6ECF-407E-8B46-5A8CB9B08AAE Q45360519-6DDBE2FD-B1D5-4385-9B79-23FB7B2E88A7

P2860

Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort

http://www.wikidata.org/entity/Q28478435

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Identification of improved IL2 ...... ross-sectional European cohort

@ast

Identification of improved IL2 ...... ross-sectional European cohort

@en

Identification of improved IL2 ...... ross-sectional European cohort

@nl

type

label

Identification of improved IL2 ...... ross-sectional European cohort

@ast

Identification of improved IL2 ...... ross-sectional European cohort

@en

Identification of improved IL2 ...... ross-sectional European cohort

@nl

prefLabel

Identification of improved IL2 ...... ross-sectional European cohort

@ast

Identification of improved IL2 ...... ross-sectional European cohort

@en

Identification of improved IL2 ...... ross-sectional European cohort

@nl

P1433

Q28478435-CFCE6D09-15F0-40A3-8A9D-86764A787C3D

P1476

Q28478435-87593028-46A0-4313-807A-586A2FFFE071

P2093

Q28478435-0BEA8E46-BE0C-484C-B608-DBF9EFD37CF3

Q28478435-177934D4-4DC9-4693-8624-58D822596185

Q28478435-2B5EBD3E-2FBD-4BA8-9114-80E444D7D40B

Q28478435-4AAE9A1A-0D03-43DA-811A-1F9D1C80A070

Q28478435-5C200C08-0F8F-4362-AA77-BCDDAE29E6D2

Q28478435-6373BFC6-F94B-4E18-B859-D23EF00C7525

Q28478435-869EC396-3956-4212-9FBC-38B2738C6D08

Q28478435-89EE02D2-81E0-4AE2-9E54-688A0DF9F134

Q28478435-9C877A3E-D60F-4629-AC64-325AA077BD7D

Q28478435-B6C08C6B-397F-4EA5-916B-DFA9DFFE8D00

P2860

Q28478435-06FF1533-2534-42E6-9331-2F8351233673

Q28478435-084311BC-C40B-47FD-BB1C-E2A074505161

Q28478435-1FB324F1-CB89-4925-935F-7D16972C346C

Q28478435-3466B053-4709-43AD-9230-4493F79B65B5

Q28478435-3F262358-137E-418D-9F09-A89C8F29B5A8

Q28478435-5023CF0E-3BF4-42DA-899B-0E90CFC16EC2

Q28478435-51576B2E-EC88-4E0D-BA71-84AA49ACC37F

Q28478435-51616FE5-EB1A-4343-ACB9-5B17D27BA343

Q28478435-53FBBDDC-226A-4D52-97B0-49F6E77644EE

Q28478435-58CEF7E2-5FD1-4E93-9DE0-F4953C098235

P2888

Q28478435-1F9392AF-EC96-48F7-9748-8B2C3DE81EC6

P304

Q28478435-3DF0EBC7-8FE9-4758-9883-1AB86386AA0C

P31

Q28478435-F06EA831-88F7-4F0E-83ED-EE1AEF648A93

P3181

Q28478435-F4DFD029-A80B-41A1-A12B-AF06FA62621B

P356

Q28478435-65BE81C1-CF9E-4998-B1D3-F0F441C9BF1C

P407

Q28478435-ECF09EE1-9325-4C6D-893D-C2BF8BC696D3

P433

Q28478435-74A0B243-FE2C-4D83-AA0F-2EB330662E10

P478

Q28478435-E0E20F05-6C1B-4749-877A-EB02A3E23CC4

P50

Q28478435-00A2468D-EAB8-4FD8-B000-8B440F9EE2FC

Q28478435-130277A4-09A7-44FE-B8CE-60AFDC969723

Q28478435-5A68D4D6-54C6-4B00-90C4-6781E6B152AF

Q28478435-5BEAAC18-DA26-4615-85F1-7CCD894B0668

Q28478435-71A94A31-969C-4292-B19D-9BC4F754448C

P577

Q28478435-D292843B-BE08-4DCD-9B11-8777CCE08E9C

P5875

Q28478435-3A149447-CB05-415D-A233-0344BA1AA13E

P6179

Q28478435-7C933337-4D12-4F7B-9520-828C1715B3DC

P698

Q28478435-4E651625-AABE-433C-AF61-93571DF2398C

P932

Q28478435-0A5D937A-CA72-479D-AA71-D24928BA8E05

P3181

P356

P1433

Genome Medicine

P1476

Identification of improved IL2 ...... ross-sectional European cohort

@en

P2093

David R Booth

http://www.w3.org/2001/XMLSchema#string

Gail Matthews

http://www.w3.org/2001/XMLSchema#string

Graeme J Stewart

http://www.w3.org/2001/XMLSchema#string

Jacob George

http://www.w3.org/2001/XMLSchema#string

Kate O'Connor

http://www.w3.org/2001/XMLSchema#string

Katherine R Smith

http://www.w3.org/2001/XMLSchema#string

Margaret Bassendine

http://www.w3.org/2001/XMLSchema#string

Maria Lorena Abate

http://www.w3.org/2001/XMLSchema#string

Martin Weltman

http://www.w3.org/2001/XMLSchema#string

Melanie Bahlo

http://www.w3.org/2001/XMLSchema#string

P2860

IL-28, IL-29 and their class II cytokine receptor IL-28R

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

A second generation human haplotype map of over 3.1 million SNPs

Fast and accurate short read alignment with Burrows-Wheeler transform

PLINK: a tool set for whole-genome association and population-based linkage analyses

Haploview: analysis and visualization of LD and haplotype maps

The Sequence Alignment/Map format and SAMtools

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study

P2888

P304

57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2174969

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/GM273

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth Powell

Golo Ahlenstiel

William L. Irving

P577

2011-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51612856

http://www.w3.org/2001/XMLSchema#string

P6179

1046157932

http://www.w3.org/2001/XMLSchema#string

P698

21884576

http://www.w3.org/2001/XMLSchema#string

P932

3238183

http://www.w3.org/2001/XMLSchema#string